vimarsana.com

Latest Breaking News On - Marine de fages - Page 1 : vimarsana.com

Aelis Farma: Ordinary General Meeting of June 28, 2022: Availability of Preparatory Documents and Participation and Voting Procedures

Regulatory News: Aelis Farma (ISIN code: FR0014007ZB4 ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the Company »),

United statesNicolas merigeauVincenzo piazzaInserm magendie neurocentreDaelis farmaAlbert marquetInserm transfert initiativeCentre broca nouvelle aquitaineNeurology of the french academy sciencesRegulatory newsOrdinary general meetingGeneral meetingInvestors generalCommercial codeSignaling specificPier vincenzo piazza

AELIS FARMA: Aelis Farma: Publication of the 2021 Annual Financial Report

Regulatory News: Aelis Farma (ISIN code: FR0014007ZB4 ticker: AELIS) (Paris: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the

United statesFrance generalNicolas merigeauVincenzo piazzaInserm magendie neurocentreDaelis farmaInserm transfert initiativeFrench financial markets authority autoritNeurology of the french academy sciencesRegulatory newsFrench financial markets authoritySignaling specificPier vincenzo piazzaGrand prixFrench academyNouvelle aquitaine region

ODDO BHF Initiates the Coverage of Aelis Farma With a Buy Recommendation

Regulatory News: Aelis Farma (ISIN code: FR0014007ZB4 ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the Company »),

United statesNicolas merigeauVincenzo piazzaInserm magendie neurocentreDaelis farmaInserm transfert initiativeNeurology of the french academy sciencesRegulatory newsGeneral meetingSignaling specificPier vincenzo piazzaGrand prixFrench academyNouvelle aquitaine regionMarine de fages

Aelis Farma, a biopharmaceutical company developing a new generation of drugs for brain diseases, announces the success of its initial public offering and raises approximately €25 million on Euronext Paris

Capital increase of approximately €25 million, i.e. 100% of the initial objective, despite high market volatility Size of the transaction which may be increased to approximately €25.55 million

United statesUnited kingdomBpifrance financementKostenloser wertpapierhandelNicolas merigeauVincenzo piazzaInserm magendie neurocentreDaelis farmaIndivior united kingdom ltdInserm transfert initiativeEuropean parliamentUnited kingdom financial conduct authorityNeurology of the french academy sciencesFinancial servicesEuropean union withdrawalCommission delegated directive

Aelis Farma, a Biopharmaceutical Company Developing a New Generation of Drugs for Brain Diseases, Launches Its Initial Public Offering on the Regulated Market of Euronext Paris

Capital increase of €25 million, which may be increased to a maximum of approximately €33 million in the event the Extension Clause and the Over-Allotment Option are fully exercised Irrevocable

United statesFrance generalUnited kingdomSouth africaComunidad autonoma de catalunaKostenloser wertpapierhandelNicolas merigeauVincenzo piazzaInserm magendie neurocentreDaelis farmaFrances levinEuropean councilNational institute of healthUnited kingdom financial conduct authorityNeurology of the french academy sciencesEuropean union withdrawal

vimarsana © 2020. All Rights Reserved.